Clinical Trial Update: An Open-Label Study of Diazoxide Choline in Patients With Genetic Obesities [Phase 2]

View source ↗

Summary

An open-label Phase 2 study evaluating diazoxide choline in patients with genetic obesities including SH2B1 deficiency obesity, PCSK1-related obesity, and SIM1 …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity Associated with Pcsk1 Mutation
• Sh2b1 Deficiency Obesity
• Sim1 Deficiency Obesity

Drugs mentioned

• diazoxide choline (diazoxide choline)

Snippet

Sponsor: Soleno Therapeutics, Inc. | Conditions: SH2B1 Deficiency Obesity, Obesity Associated With PCSK1 Mutation (rs6232 Variant) | Phase 2 | Status: UNKNOWN